Option Care Health (OPCH) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $1,493.5M, up 4.1% YoY; GAAP net income rose 10.8% to $57.4M and diluted EPS increased to $0.38 from $0.32.

• Adjusted EBITDA rose 4.3% to $124.6M and adjusted diluted EPS increased 8.9% to $0.49.

Financial highlights

• Q3 gross profit was $285.0M versus $272.9M; gross margin was 19.1% versus 19.0%. Operating income was $89.2M versus $84.5M.

• Nine-month revenue was $4,286.6M versus $4,184.1M; net income was $156.7M versus $149.1M, and diluted EPS was $1.02 versus $0.91.

• Nine-month gross profit rose 1.1% to $814.2M as gross margin eased to 19.0% from 19.2%; operating income was $246.9M versus $246.4M.

• Nine-month SG&A rose 1.3% to $516.9M, including merger costs and growth investments; adjusted EBITDA was $346.9M versus $345.3M and adjusted diluted EPS was $1.34 versus $1.26.

Outlook and guidance

• Chronic inflammatory disease (CID) dynamics are expected to reduce 2026 gross profit by ~$55M.

• Previously disclosed financial guidance was withdrawn due to the pending acquisition; existing cash, expected operating cash flows and credit availability are expected to cover operating requirements and planned capital expenditures for the next 12 months and beyond.